vs
Progyny, Inc.（PGNY）とSotera Health Co（SHC）の財務データ比較。上の社名をクリックして会社を切り替えられます
Progyny, Inc.の直近四半期売上が大きい（$318.4M vs $303.4M、Sotera Health Coの約1.0倍）。Sotera Health Coの純利益率が高く（11.5% vs 3.9%、差は7.6%）。Progyny, Inc.の前年同期比売上増加率が高い（6.7% vs 4.6%）。Sotera Health Coの直近四半期フリーキャッシュフローが多い（$52.4M vs $48.6M）。過去8四半期でSotera Health Coの売上複合成長率が高い（10.6% vs 7.0%）
Progyny, Inc.は米国を中心に事業を展開する有力な不妊治療・家族形成支援福利厚生サービスプロバイダーです。企業顧客と提携し、体外受精、妊孕性温存、養子縁組支援、代理出産サポートなどの福利厚生を提供し、多様な業種の従業員にサービスを届けています。
Sotera Health Coは医療安全ソリューションをグローバルに提供する企業で、医療機器メーカー、製薬会社、食品・消費財企業を対象に滅菌サービス、分析検査、規制対応コンサルティングを提供し、顧客の製品安全性確保と基準準拠を支援しています。
PGNY vs SHC — 直接比較
損益計算書 — Q4 2025 vs Q4 2025
| 指標 | | |
|---|---|---|
| 売上 | $318.4M | $303.4M |
| 純利益 | $12.5M | $34.8M |
| 粗利率 | 24.1% | 54.7% |
| 営業利益率 | 4.8% | 23.2% |
| 純利益率 | 3.9% | 11.5% |
| 売上前年比 | 6.7% | 4.6% |
| 純利益前年比 | 18.5% | 182.8% |
| EPS（希薄化後） | $0.14 | $0.12 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $318.4M | $303.4M | ||
| Q3 25 | $313.3M | $311.3M | ||
| Q2 25 | $332.9M | $294.3M | ||
| Q1 25 | $324.0M | $254.5M | ||
| Q4 24 | $298.4M | $290.2M | ||
| Q3 24 | $286.6M | $285.5M | ||
| Q2 24 | $304.1M | $276.6M | ||
| Q1 24 | $278.1M | $248.2M |
| Q4 25 | $12.5M | $34.8M | ||
| Q3 25 | $13.9M | $48.4M | ||
| Q2 25 | $17.1M | $8.0M | ||
| Q1 25 | $15.1M | $-13.3M | ||
| Q4 24 | $10.5M | $12.3M | ||
| Q3 24 | $10.4M | $17.0M | ||
| Q2 24 | $16.5M | $8.8M | ||
| Q1 24 | $16.9M | $6.3M |
| Q4 25 | 24.1% | 54.7% | ||
| Q3 25 | 23.2% | 57.0% | ||
| Q2 25 | 23.7% | 56.6% | ||
| Q1 25 | 23.4% | 53.2% | ||
| Q4 24 | 21.3% | 56.6% | ||
| Q3 24 | 20.7% | 55.4% | ||
| Q2 24 | 22.5% | 55.2% | ||
| Q1 24 | 22.4% | 51.2% |
| Q4 25 | 4.8% | 23.2% | ||
| Q3 25 | 6.9% | 23.4% | ||
| Q2 25 | 7.3% | 6.4% | ||
| Q1 25 | 7.5% | -5.8% | ||
| Q4 24 | 5.3% | 30.0% | ||
| Q3 24 | 4.3% | 28.2% | ||
| Q2 24 | 6.8% | 27.8% | ||
| Q1 24 | 6.7% | 21.4% |
| Q4 25 | 3.9% | 11.5% | ||
| Q3 25 | 4.4% | 15.5% | ||
| Q2 25 | 5.1% | 2.7% | ||
| Q1 25 | 4.6% | -5.2% | ||
| Q4 24 | 3.5% | 4.2% | ||
| Q3 24 | 3.6% | 6.0% | ||
| Q2 24 | 5.4% | 3.2% | ||
| Q1 24 | 6.1% | 2.5% |
| Q4 25 | $0.14 | $0.12 | ||
| Q3 25 | $0.15 | $0.17 | ||
| Q2 25 | $0.19 | $0.03 | ||
| Q1 25 | $0.17 | $-0.05 | ||
| Q4 24 | $0.12 | $0.05 | ||
| Q3 24 | $0.11 | $0.06 | ||
| Q2 24 | $0.17 | $0.03 | ||
| Q1 24 | $0.17 | $0.02 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $112.2M | $344.6M |
| 総負債低いほど良い | — | $2.1B |
| 株主資本純資産 | $516.0M | $606.0M |
| 総資産 | $742.4M | $3.3B |
| 負債/資本比率低いほどレバレッジが低い | — | 3.53× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $112.2M | $344.6M | ||
| Q3 25 | $134.0M | $299.2M | ||
| Q2 25 | $132.5M | $332.4M | ||
| Q1 25 | $109.2M | $304.4M | ||
| Q4 24 | $162.3M | $277.2M | ||
| Q3 24 | $91.5M | $306.7M | ||
| Q2 24 | $95.0M | $246.1M | ||
| Q1 24 | $115.0M | $261.1M |
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | $516.0M | $606.0M | ||
| Q3 25 | $560.0M | $550.5M | ||
| Q2 25 | $515.0M | $511.3M | ||
| Q1 25 | $467.2M | $414.1M | ||
| Q4 24 | $422.1M | $404.9M | ||
| Q3 24 | $434.9M | $470.2M | ||
| Q2 24 | $456.2M | $422.8M | ||
| Q1 24 | $571.6M | $429.4M |
| Q4 25 | $742.4M | $3.3B | ||
| Q3 25 | $795.2M | $3.2B | ||
| Q2 25 | $761.0M | $3.2B | ||
| Q1 25 | $730.3M | $3.1B | ||
| Q4 24 | $607.1M | $3.1B | ||
| Q3 24 | $660.0M | $3.1B | ||
| Q2 24 | $698.6M | $3.1B | ||
| Q1 24 | $794.3M | $3.1B |
| Q4 25 | — | 3.53× | ||
| Q3 25 | — | 3.89× | ||
| Q2 25 | — | 4.34× | ||
| Q1 25 | — | 5.36× | ||
| Q4 24 | — | 5.49× | ||
| Q3 24 | — | 4.73× | ||
| Q2 24 | — | 5.26× | ||
| Q1 24 | — | 5.19× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $54.2M | $103.1M |
| フリーキャッシュフロー営業CF - 設備投資 | $48.6M | $52.4M |
| FCFマージンFCF / 売上 | 15.3% | 17.3% |
| 設備投資強度設備投資 / 売上 | 1.8% | 16.7% |
| キャッシュ転換率営業CF / 純利益 | 4.34× | 2.96× |
| 直近12ヶ月FCF直近4四半期 | $191.8M | $149.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $54.2M | $103.1M | ||
| Q3 25 | $50.7M | $71.2M | ||
| Q2 25 | $55.5M | $57.4M | ||
| Q1 25 | $49.8M | $55.5M | ||
| Q4 24 | $52.2M | $55.7M | ||
| Q3 24 | $44.5M | $97.5M | ||
| Q2 24 | $56.7M | $61.3M | ||
| Q1 24 | $25.7M | $9.7M |
| Q4 25 | $48.6M | $52.4M | ||
| Q3 25 | $46.0M | $35.0M | ||
| Q2 25 | $50.2M | $26.2M | ||
| Q1 25 | $47.0M | $35.6M | ||
| Q4 24 | $50.3M | $-10.2M | ||
| Q3 24 | $42.7M | $61.1M | ||
| Q2 24 | $55.8M | $19.4M | ||
| Q1 24 | $24.9M | $-25.2M |
| Q4 25 | 15.3% | 17.3% | ||
| Q3 25 | 14.7% | 11.2% | ||
| Q2 25 | 15.1% | 8.9% | ||
| Q1 25 | 14.5% | 14.0% | ||
| Q4 24 | 16.8% | -3.5% | ||
| Q3 24 | 14.9% | 21.4% | ||
| Q2 24 | 18.4% | 7.0% | ||
| Q1 24 | 8.9% | -10.2% |
| Q4 25 | 1.8% | 16.7% | ||
| Q3 25 | 1.5% | 11.6% | ||
| Q2 25 | 1.6% | 10.6% | ||
| Q1 25 | 0.9% | 7.8% | ||
| Q4 24 | 0.6% | 22.7% | ||
| Q3 24 | 0.6% | 12.7% | ||
| Q2 24 | 0.3% | 15.2% | ||
| Q1 24 | 0.3% | 14.1% |
| Q4 25 | 4.34× | 2.96× | ||
| Q3 25 | 3.65× | 1.47× | ||
| Q2 25 | 3.24× | 7.21× | ||
| Q1 25 | 3.31× | — | ||
| Q4 24 | 4.95× | 4.52× | ||
| Q3 24 | 4.27× | 5.73× | ||
| Q2 24 | 3.44× | 7.00× | ||
| Q1 24 | 1.52× | 1.53× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PGNY
| Fertility Benefit Services | $208.6M | 66% |
| Pharmacy Benefit Services | $109.8M | 34% |
SHC
| Transferred At Point In Time | $198.4M | 65% |
| Nelson Labs | $55.2M | 18% |
| Nordion | $49.8M | 16% |
